Skip to main content

Publications

featured publications

  • Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study.

    Haemophilia : the official journal of the World Federation of Hemophilia

    Authors: K John Pasi, Kathelijn Fischer, Margaret Ragni, Roshni Kulkarni, Margareth C Ozelo, Johnny Mahlangu, Amy Shapiro, Stephanie P'Ng, Hervé Chambost, Beatrice Nolan, Carolyn Bennett, Tadashi Matsushita, Bent Winding, Joachim Fruebis, Huixing Yuan, Dan Rudin, Johannes Oldenburg

  • Coagulopathy in COVID-19 and Its Implication for Safe and Efficacious Thromboprophylaxis.

    Hamostaseologie

    Authors: Florian Langer, Stefan Kluge, Robert Klamroth, Johannes Oldenburg

  • Selective Modulation of the Protease Activated Protein C Using Exosite Inhibiting Aptamers.

    Nucleic acid therapeutics

    Authors: Nasim Shahidi Hamedani, Jens Müller, Fabian Tolle, Heiko Rühl, Behnaz Pezeshkpoor, Kerstin Liphardt, Johannes Oldenburg, Günter Mayer, Bernd Pötzsch

  • octanate: over 20 years of clinical experience in overcoming challenges in haemophilia A treatment.

    Therapeutic advances in hematology

    Authors: Anna Klukowska, Vladimír Komrska, Vladimír Vdovin, Nadezhda Zozulya, Toshko Lissitchkov, Johannes Oldenburg, Carmen Escuriola Ettingshausen

  • Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study.

    Haemophilia : the official journal of the World Federation of Hemophilia

    Authors: Beatrice Nolan, Johnny Mahlangu, Ingrid Pabinger, Guy Young, Barbara A Konkle, Chris Barnes, Keiji Nogami, Elena Santagostino, K John Pasi, Liane Khoo, Bent Winding, Huixing Yuan, Joachim Fruebis, Dan Rudin, Johannes Oldenburg

  • Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case-control study.

    British journal of haematology

    Authors: Alice S van Velzen, Corien L Eckhardt, Marjolein Peters, Johannes Oldenburg, Marjon Cnossen, Ri Liesner, Massimo Morfini, Giancarlo Castaman, Simon McRae, Johanna G van der Bom, Karin Fijnvandraat

  • The Current Understanding of Molecular Pathogenesis of Quantitative von Willebrand Disease, Types 1 and 3.

    Hamostaseologie

    Authors: Hamideh Yadegari, Johannes Oldenburg

  • A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.

    Blood

    Authors: Guy Young, Ri Liesner, Tiffany Chang, Robert Sidonio, Johannes Oldenburg, Victor Jiménez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Marianne Uguen, Michelle Y Doral, Lilyan Y Wright, Christophe Schmitt, Gallia G Levy, Midori Shima, Maria Elisa Mancuso

  • Clinical manifestation of hemophilia A in the absence of mutations in the F8 gene that encodes FVIII: role of microRNAs.

    Transfusion

    Authors: Katarzyna I Jankowska, Joseph McGill, Behnaz Pezeshkpoor, Johannes Oldenburg, Chintamani D Atreya, Zuben E Sauna

  • Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.

    Blood

    Authors: Amy D Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Pratima Chowdary, Hermann Eichler, Victor Jiménez-Yuste, Kaan Kavakli, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P Wheeler, Guy Young, Silva Zupancic-Salek, Johannes Oldenburg